

Ju Dong Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1357869/publications.pdf>

Version: 2024-02-01

107
papers

7,243
citations

101384

36
h-index

62479

80
g-index

121
all docs

121
docs citations

121
times ranked

9469
citing authors

#	ARTICLE	IF	CITATIONS
1	A global view of hepatocellular carcinoma: trends, risk, prevention and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 589-604.	8.2	2,482
2	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	2.9	416
3	The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. <i>Seminars in Cancer Biology</i> , 2011, 21, 35-43.	4.3	322
4	Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 64-70.	2.4	216
5	New advances in the diagnosis and management of hepatocellular carcinoma. <i>BMJ, The</i> , 2020, 371, m3544.	3.0	210
6	Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 422-436.	3.6	200
7	Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 103-111.	3.7	177
8	Epidemiology and Management of Hepatocellular Carcinoma. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 899-919.	1.9	166
9	HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 128-139.	1.8	139
10	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 531-538.	1.1	135
11	Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. <i>Nature Communications</i> , 2020, 11, 4489.	5.8	134
12	A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 64, 85-91.	3.6	128
13	Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 714-723.	0.9	125
14	Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 859-860.	1.8	123
15	Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 907-916.	3.6	123
16	Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 617-623.e1.	2.4	116
17	Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 767-775.e3.	2.4	112
18	Model to estimate survival in ambulatory patients with hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 614-621.	3.6	83

#	ARTICLE	IF	CITATIONS
19	Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. <i>Hepatology</i> , 2016, 63, 148-158.	3.6	72
20	Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986912.	1.4	70
21	Biliary Tract Cancers in Olmsted County, Minnesota, 1976â€“2008. <i>American Journal of Gastroenterology</i> , 2012, 107, 1256-1262.	0.2	68
22	Hepatocellular Carcinoma Occurs at an Earlier Age in Africans, Particularly in Association With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2015, 110, 1629-1631.	0.2	68
23	Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. <i>Journal of Viral Hepatitis</i> , 2019, 26, 596-602.	1.0	67
24	MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. <i>Journal of Hepatology</i> , 2022, 76, 781-787.	1.8	67
25	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 127-131.e2.	2.4	66
26	Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. <i>American Journal of Gastroenterology</i> , 2016, 111, 1573-1580.	0.2	61
27	Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA. <i>Theranostics</i> , 2019, 9, 7239-7250.	4.6	59
28	Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. <i>Liver International</i> , 2018, 38, 136-143.	1.9	58
29	Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2018, 38, 160-169.	1.8	50
30	Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. <i>PLoS ONE</i> , 2014, 9, e92273.	1.1	49
31	Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. <i>Cancer</i> , 2017, 123, 81-89.	2.0	46
32	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. <i>Hepatology</i> , 2018, 68, 78-88.	3.6	45
33	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1085-1092.	1.1	43
34	The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1531-1541.	3.0	43
35	Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 335-343.	4.5	42
36	<i>Sleeping Beauty</i> Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors. <i>Cancer Research</i> , 2017, 77, 6576-6588.	0.4	40

#	ARTICLE	IF	CITATIONS
37	Hepatocellular Carcinoma in Olmsted County, Minnesota, 1976-2008. Mayo Clinic Proceedings, 2012, 87, 9-16.	1.4	39
38	The incidence rates and survival of gallbladder cancer in the USA. European Journal of Cancer Prevention, 2019, 28, 1-9.	0.6	36
39	Metformin does not improve survival in patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 15750.	1.4	33
40	Role of admission serum albumin levels in patients with intracerebral hemorrhage. Acta Neurologica Belgica, 2016, 116, 27-30.	0.5	32
41	Surveillance for Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2012, 10, 16-21.	2.4	31
42	Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. Hepatology, 2021, 74, 2622-2632.	3.6	31
43	The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma. Cancers, 2021, 13, 3076.	1.7	30
44	Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota. Journal of Clinical Gastroenterology, 2017, 51, 742-748.	1.1	29
45	More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver International, 2018, 38, 895-902.	1.9	27
46	Circulating Tumor DNA and Hepatocellular Carcinoma. Seminars in Liver Disease, 2019, 39, 452-462.	1.8	27
47	State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States. Hepatology, 2021, 74, 1384-1394.	3.6	26
48	Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. Liver Cancer, 2017, 6, 126-136.	4.2	23
49	Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation. Liver Transplantation, 2018, 24, 44-55.	1.3	23
50	Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. Journal of the American College of Surgeons, 2021, 232, 361-371.	0.2	23
51	Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States. Clinical Gastroenterology and Hepatology, 2023, 21, 670-680.e18.	2.4	22
52	Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors. Annals of Surgery, 2018, 268, 1043-1050.	2.1	18
53	Diagnostic Criteria and LI-RADS for Hepatocellular Carcinoma. Clinical Liver Disease, 2021, 17, 409-413.	1.0	18
54	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology, 2022, 76, 1649-1659.	3.6	18

#	ARTICLE	IF	CITATIONS
55	Feasibility of circulating tumor DNA testing in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 745-750.	0.6	17
56	Optimal endoscopy timing according to the severity of underlying liver disease in patients with acute variceal bleeding. <i>Digestive and Liver Disease</i> , 2019, 51, 993-998.	0.4	17
57	Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. <i>Liver Cancer</i> , 2021, 10, 407-418.	4.2	17
58	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 974-983.	2.4	16
59	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	2.4	15
60	Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 1922-1932.	1.9	15
61	Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 479.	1.8	15
62	Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation. <i>Cancer Medicine</i> , 2018, 7, 5870-5878.	1.3	14
63	Knowledge, Attitudes, and Behaviors of Viral Hepatitis Among Recent African Immigrants in the United States: A Community Based Participatory Research Qualitative Study. <i>Frontiers in Public Health</i> , 2020, 8, 25.	1.3	14
64	Single-cell mass cytometry on peripheral blood identifies immune cell subsets associated with primary biliary cholangitis. <i>Scientific Reports</i> , 2020, 10, 12584.	1.6	13
65	Decreasing Trend of Serum α -Fetoprotein Level in Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1177-1179.e4.	2.4	13
66	Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018. <i>Hepatology Communications</i> , 2022, 6, 2253-2261.	2.0	13
67	Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1157-e1169.	2.4	12
68	Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis. <i>Hepatology</i> , 2023, 77, 546-557.	3.6	12
69	Weekend Admission for Acute Cholangitis Does Not Adversely Impact Clinical or Endoscopic Outcomes. <i>Digestive Diseases and Sciences</i> , 2016, 61, 53-61.	1.1	11
70	BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study. <i>Hpb</i> , 2021, 23, 762-769.	0.1	11
71	Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1692-1701.	2.8	9
72	DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. <i>Hepatology Communications</i> , 2021, 5, 1448-1459.	2.0	8

#	ARTICLE	IF	CITATIONS
73	High Neutrophilâ€“Lymphocyte Ratio and Delta Neutrophilâ€“Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	8
74	Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact. <i>Hepatology Communications</i> , 2022, 6, 223-236.	2.0	8
75	Circulating Tumor Cellâ€“Based Messenger RNA Scoring System for Prognostication of Hepatocellular Carcinoma: Translating Tissueâ€“Based Messenger RNA Profiling Into a Noninvasive Setting. <i>Liver Transplantation</i> , 2022, 28, 200-214.	1.3	8
76	Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1179-1190.	1.4	7
77	Early Detection of Hepatocellular Carcinoma: Expanding the Utility of Circulating Tumor Markers. <i>Hepatology</i> , 2019, 69, 1855-1857.	3.6	6
78	Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis?. <i>Gut</i> , 2017, 66, 4-5.	6.1	5
79	Green tea consumption: A potential chemopreventive measure for hepatocellular carcinoma?. <i>Hepatology</i> , 2018, 67, 10-12.	3.6	5
80	Estrogen-Driven Growth of Focal Nodular Hyperplasia: Truth or Myth?. <i>ACG Case Reports Journal</i> , 2021, 8, e00531.	0.2	5
81	Increase in Alcoholic Hepatitis as an Etiology for Liver Transplantation in the United States: A 2004â€“2018 Analysis. <i>Transplantation Direct</i> , 2020, 6, e612.	0.8	5
82	Hepatic sinusoidal obstruction syndrome due to tacrolimus in a liver-transplantation recipient. <i>Gastroenterology Report</i> , 2021, 9, 485-487.	0.6	4
83	Covalent Chemistryâ€“Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. <i>Advanced Materials Technologies</i> , 2021, 6, 2001056.	3.0	4
84	Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. <i>Gut and Liver</i> , 2010, 4, 537-542.	1.4	4
85	Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. <i>Transplantation Direct</i> , 2021, 7, e635.	0.8	4
86	Emerging drugs for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 141-149.	1.0	4
87	Reply. <i>Hepatology</i> , 2015, 61, 1094-1094.	3.6	2
88	Damned if you do, damned if you don't: The evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with directâ€“acting antivirals for hepatitis C virus. <i>Liver International</i> , 2017, 37, 809-811.	1.9	2
89	Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa â€“ Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 394.	3.7	2
90	Does cirrhosis associated with well controlled viral hepatitis confer a risk for extrahepatic cancer?. <i>Hepatology</i> , 2018, 68, 1217-1219.	3.6	2

#	ARTICLE	IF	CITATIONS
91	Screening Indications and Treatments for Cholangiocarcinoma. <i>Current Hepatology Reports</i> , 2019, 18, 408-416.	0.4	2
92	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1814.	2.4	1
93	Management of Combined Hepatocellular Carcinoma-Cholangiocarcinoma. <i>Current Hepatology Reports</i> , 2018, 17, 385-391.	0.4	1
94	Nuclear size of circulating tumor cells in advanced prostate cancer to reveal a potential biomarker for clinical outcomes and androgen receptor indifference.. <i>Journal of Clinical Oncology</i> , 2021, 39, 167-167.	0.8	1
95	Multi-target blood test to improve the performance of hepatocellular carcinoma surveillance programs: A modeling-based virtual trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 405-405.	0.8	1
96	Early detection of primary liver cancer using plasma cell-free DNA fragmentomics: Do all the pieces come together?. <i>Hepatology</i> , 2022, 76, 289-291.	3.6	1
97	Reply to: "Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence", <i>Journal of Hepatology</i> , 2017, 67, 1357.	1.8	0
98	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1684.	2.4	0
99	REPLY.. <i>Hepatology</i> , 2020, 72, 362-363.	3.6	0
100	Reply. <i>Hepatology</i> , 2020, 72, 364-365.	3.6	0
101	Sex differences in age at waitlist registration for liver transplantation with nonalcoholic steatohepatitis as primary indication. <i>Clinical Transplantation</i> , 2021, 35, e14163.	0.8	0
102	Liver Mass in a Young Male With Ollier Disease. <i>Gastroenterology</i> , 2021, 161, e4-e5.	0.6	0
103	A morphological subset of circulating tumor cells in advanced prostate cancer reveals a potential biomarker for clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, e17008-e17008.	0.8	0
104	Abstract 764: Circulating tumor cell-based mRNA scoring system for prognostication of hepatocellular carcinoma - Translating HCC tissue-based mRNA profiling into a non-invasive setting. , 2021, , .		0
105	Circulating tumor cells with small nuclear size: A novel biomarker for survival and clinical outcomes in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17512-e17512.	0.8	0
106	Association of very small nuclear circulating tumor cell (vsnCTC) with clinical outcomes in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 168-168.	0.8	0
107	A prospective trial to evaluate the performance of the multitarget hepatocellular carcinoma blood test (mt-HBT) for screening at-risk patients: The Altus study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS486-TPS486.	0.8	0